Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study

Bilici, A; Olmez, OF; Kaplan, MA; Oksuzoglu, B; Sezer, A; Karadurmus, N; Cubukcu, E; Sendur, MAN; Aksoy, S; Erdem, D; Basaran, G; Cakar, B; Shbair, ATM; Arslan, C; Sumbul, AT; Goksu, SS; Karadag, I; Cicin, I; Gumus, M; Selcukbiricik, F; Harputluoglu, H; Demirci, U

Bilici, A (通讯作者)，Istanbul Medipol Univ, Medipol Mega Hosp, Fac Med, TEM Avrupa Otoyolu Goztepe Cikisi 1, TR-34214 Istanbul, Turkiye.

ACTA ONCOLOGICA, 2023; 62 (4): 381

Abstract

AimTo investigate the pathological complete response (pCR) achieved after neoadjuvant therapy with versus without adding pertuzumab (P) to trastuzumab......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索